

LEMAITRE VASCULAR INC  
Form 10-Q  
November 06, 2015  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2015**

**Or**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_.**

**Commission File Number 001-33092**

**LEMAITRE VASCULAR, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**04-2825458**  
**(I.R.S. Employer**  
**Identification No.)**

**43 Second Avenue, Burlington, Massachusetts**  
**(Address of principal executive offices)**  
**(781) 221-2266**

**01803**  
**(Zip Code)**

**(Registrant's telephone number, including area code)**

**63 Second Avenue**  
**Burlington, MA 01803**

**(Former name or former address, if changed since last report)**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer   
Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company   
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The registrant had 18,116,429 shares of common stock, \$.01 par value per share, outstanding as of November 2, 2015.

**Table of Contents**

**LEMAITRE VASCULAR**

**FORM 10-Q**

**TABLE OF CONTENTS**

	Page
Part I. <u>Financial Information:</u>	
Item 1. <u>Financial Statements</u>	
<u>Consolidated Balance Sheets as of September 30, 2015 (unaudited) and December 31, 2014</u>	3
<u>Unaudited Consolidated Statements of Operations for the three-month and nine-month periods ended September 30, 2015 and 2014</u>	4
<u>Unaudited Consolidated Statements of Comprehensive Income for the three-month and nine-month periods ended September 30, 2015 and 2014</u>	5
<u>Unaudited Consolidated Statements of Cash Flows for the nine-month periods ended September 30, 2015 and 2014</u>	6
<u>Notes to Unaudited Consolidated Financial Statements</u>	7
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	18
Item 3. <u>Quantitative and Qualitative Disclosure about Market Risk</u>	29
Item 4. <u>Controls and Procedures</u>	29
Part II. <u>Other Information:</u>	
Item 1. <u>Legal Proceedings</u>	30
Item 1A. <u>Risk Factors</u>	30
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	30
Item 6. <u>Exhibits</u>	31
<u>Signatures</u>	32
<u>Index to Exhibits</u>	33

**Table of Contents****Part I. Financial Information****Item 1. Financial Statements****LeMaitre Vascular, Inc.****Consolidated Balance Sheets**

	(unaudited)	
	<b>September 30, 2015</b>	<b>December 31, 2014</b>
	(in thousands, except share data)	
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 23,629	\$ 18,692
Accounts receivable, net of allowances of \$253 at September 30, 2015 and \$242 at December 31, 2014	11,339	10,803
Inventory	15,920	16,714
Prepaid expenses and other current assets	3,089	2,379
<b>Total current assets</b>	<b>53,977</b>	<b>48,588</b>
Property and equipment, net	6,788	6,878
Goodwill	17,717	17,281
Other intangibles, net	6,656	7,157
Deferred tax assets	1,306	1,418
Other assets	168	170
<b>Total assets</b>	<b>\$ 86,612</b>	<b>\$ 81,492</b>
<b>Liabilities and stockholders equity</b>		
Current liabilities:		
Accounts payable	\$ 931	\$ 1,127
Accrued expenses	7,598	7,479
Acquisition-related obligations	304	1,435
<b>Total current liabilities</b>	<b>8,833</b>	<b>10,041</b>
Deferred tax liabilities	2,917	2,919
Other long-term liabilities	676	325
<b>Total liabilities</b>	<b>12,426</b>	<b>13,285</b>
Stockholders equity:		
Preferred stock, \$0.01 par value; authorized 3,000,000 shares; none outstanding		
Common stock, \$0.01 par value; authorized 37,000,000 shares; issued 19,499,818 shares at September 30, 2015, and 18,778,436 shares at December 31, 2014	195	188
Additional paid-in capital	80,188	75,389

Edgar Filing: LEMAITRE VASCULAR INC - Form 10-Q

Retained earnings	6,356	3,248
Accumulated other comprehensive loss	(4,033)	(2,365)
Treasury stock, at cost; 1,431,139 shares at September 30, 2015, and 1,407,211 shares at December 31, 2014	(8,520)	(8,253)
Total stockholders' equity	74,186	68,207
Total liabilities and stockholders' equity	\$ 86,612	\$ 81,492

See accompanying notes to consolidated financial statements.

Table of Contents

## LeMaitre Vascular, Inc.

## Consolidated Statements of Operations

(unaudited)

	For the three months ended September 30,		For the nine months ended September 30,	
	2015	2014	2015	2014
	(in thousands, except per share data)			
Net sales	\$ 19,025	\$ 17,501	\$ 57,869	\$ 52,416
Cost of sales	5,509	5,498	18,106	16,813
Gross profit	13,516	12,003	39,763	35,603
Sales and marketing	5,489	5,091	16,866	16,857
General and administrative	3,455	3,765	10,375	10,376
Research and development	1,421	1,109	3,904	3,590
Medical device excise tax	190	178	554	518
Restructuring charges		8		500
Impairment charges				161
Gain on divestiture	(360)		(360)	
Total operating expenses	10,195	10,151	31,339	32,002
Income from operations	3,321	1,852	8,424	3,601
Other income (expense):				
Interest income	3	1	7	2
Interest expense		(6)		(6)
Foreign currency gain (loss)	(185)	52	(142)	30
Income before income taxes	3,139	1,899	8,289	3,627
Provision for income taxes	1,047	965	3,061	1,628
Net income	\$ 2,092	\$ 934	\$ 5,228	\$ 1,999
Earnings per share of common stock:				
Basic	\$ 0.12	\$ 0.05	\$ 0.30	\$ 0.12
Diluted	\$ 0.11	\$ 0.05	\$ 0.29	\$ 0.12
Weighted-average shares outstanding:				
Basic	17,865	17,348	17,625	16,358

Edgar Filing: LEMAITRE VASCULAR INC - Form 10-Q

Diluted	18,497	17,709	18,136	16,772
Cash dividends declared per common share	\$ 0.040	\$ 0.035	\$ 0.120	\$ 0.105

See accompanying notes to consolidated financial statements.



Table of Contents

## LeMaitre Vascular, Inc.

## Consolidated Statements of Comprehensive Income

(unaudited)

	Three months ended September 30, 2015		Nine months ended September 30, 2015	
	2014	2014	2014	2014
	(in thousands)			
Net income	\$ 2,092	\$ 934	\$ 5,228	\$ 1,999
Other comprehensive loss:				
Foreign currency translation adjustment, net	(508)	(1,378)	(1,668)	(1,375)
Total other comprehensive loss	(508)	(1,378)	(1,668)	(1,375)
Comprehensive income (loss)	\$ 1,584	\$ (444)	\$ 3,560	\$ 624

See accompanying notes to consolidated financial statements.

**Table of Contents****LeMaitre Vascular, Inc.****Consolidated Statements of Cash Flows****(unaudited)**

	<b>For the nine months ended September 30,</b>	
	<b>2015</b>	<b>2014</b>
	(in thousands)	
<b>Operating activities</b>		
Net income	\$ 5,228	\$ 1,999
Adjustments to reconcile net income to net cash provided by (used in) operating activities:		
Depreciation and amortization	2,497	2,422
Stock-based compensation	1,088	982
Accrued contingent earnout		138
Impairment charges		161
Provision of doubtful accounts	156	31
Provision for inventory write-downs	462	508
Excess tax benefits from stock-based compensation awards		(28)
Loss on disposal of property and equipment		4
Gain on divestitures	(360)	
Foreign currency transaction gain	130	2
Changes in operating assets and liabilities:		
Accounts receivable	(1,078)	(194)
Inventory	(33)	(2,488)
Prepaid expenses and other assets	(791)	(403)
Accounts payable and other liabilities	214	(304)
<b>Net cash provided by operating activities</b>	<b>7,513</b>	<b>2,830</b>
<b>Investing activities</b>		
Purchases of property and equipment	(1,558)	(774)
Proceeds from disposal of property and equipment	15	
Proceeds from divestitures, net of expenses	360	
Payments related to acquisitions, net of cash acquired	(1,426)	(5,577)
Purchase of intellectual property	(6)	(9)
<b>Net cash used in investing activities</b>	<b>(2,615)</b>	<b>(6,360)</b>
<b>Financing activities</b>		
Payments of long-term debt		(1,133)
Payment of deferred acquisition consideration	(1,100)	(366)
Proceeds from issuance of common stock	3,718	10,834
Purchase of treasury stock	(266)	(211)
Common stock cash dividend paid	(2,120)	(1,700)

Excess tax benefits from stock-based compensation awards		28
Net cash provided by (used in) financing activities	232	7,452
Effect of exchange rate changes on cash and cash equivalents	(193)	(279)
Net increase in cash and cash equivalents	4,937	3,643
Cash and cash equivalents at beginning of period	18,692	14,711
Cash and cash equivalents at end of period	\$ 23,629	\$ 18,354

Supplemental disclosures of cash flow information (see Note 13)

See accompanying notes to consolidated financial statements.

**Table of Contents**

**LeMaitre Vascular, Inc.**

**Notes to Consolidated Financial Statements**

**September 30, 2015**

**(unaudited)**

**1. Organization and Basis for Presentation**

***Description of Business***

Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We operate in a single segment in which our principal product lines include the following: valvulotomes, balloon catheters, carotid shunts, biologic patches, biologic grafts, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, angioscopes, and powered phlebectomy devices. Our offices are located in Burlington, Massachusetts; Mississauga, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; North Melbourne, Australia; Tokyo, Japan; and Shanghai, China.

***Basis of Presentation***

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal, recurring adjustments considered necessary for a fair presentation of the results of these interim periods have been included. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are updated as appropriate. The results for the nine months ended September 30, 2015 are not necessarily indicative of results to be expected for the entire year. The information contained in these interim financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2014, including the notes thereto, included in our Form 10-K filed with the Securities and Exchange Commission (SEC).

***Consolidation***

Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

***Recent Accounting Pronouncements***

In May 2014, the Financial Accounting Standards Board issued a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in GAAP. Under this standard, revenue will be recognized to depict the

transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This standard will be effective for annual reporting periods beginning after December 15, 2017, allows for either full retrospective or modified retrospective application, and early adoption is not permitted. We are assessing the new standard and which adoption method we will apply. We have not yet determined the impact on our results of operations.

## **2. Income Tax Expense**

As part of the process of preparing our consolidated financial statements we are required to determine our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax expense together with assessing temporary differences resulting from recognition of items for income tax and accounting purposes.

**Table of Contents**

These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from taxable income during the carryback period or in the future; and to the extent we believe that recovery is not more likely than not, we must establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we must reflect this increase as an expense within the tax provision in the statement of operations. We do not provide for income taxes on undistributed earnings of foreign subsidiaries, as our intention is to permanently reinvest these earnings.

We recognize, measure, present and disclose in our financial statements any uncertain tax positions that we have taken, or expect to take on a tax return. We operate in multiple taxing jurisdictions, both within and without the United States, and may be subject to audits from various tax authorities. Management's judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We will monitor the realizability of our deferred tax assets and adjust the valuation allowance accordingly.

Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.

Our 2015 income tax expense varies from the statutory rate mainly due to certain permanent items, offset by lower statutory rates from our foreign entities and a discrete item for stock option exercises. Our 2014 income tax expense varies from the statutory rate mainly due to certain permanent items, offset by lower statutory rates from our foreign entities, and discrete items related to certain foreign branch losses previously not deductible and the release of a valuation allowance on certain foreign loss carryforwards.

We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of September 30, 2015, the gross amount of unrecognized tax benefits exclusive of interest and penalties was \$72,000. We remain subject to examination until the statute of limitations expires for each respective tax jurisdiction. The statute of limitations will be open with respect to these tax positions until 2024. A reconciliation of the beginning and ending amount of our unrecognized tax benefits is as follows:

	<b>2015</b> (in thousands)
Unrecognized tax benefits at the beginning of year	\$ 23
Additions for tax positions of current year	49
Additions for tax positions of prior years	
Reductions for settlements with taxing authorities	
Reductions for lapses of the applicable statutes of limitations	
Unrecognized tax benefits at the end of the period	\$ 72

In September 2015, the Internal Revenue Service notified us that our 2013 Federal tax return would be audited. We expect the audit to commence during the fourth quarter of 2015. We believe there will be no material changes to our income tax liability as a result of this audit. As of September 30, 2015, a summary of the tax years that remain subject to examination in our taxing jurisdictions is as follows:

United States	2012 and forward
Foreign	2008 and forward

**Table of Contents****3. Inventories**

Inventories consist of the following:

	<b>September 30, 2015</b>	<b>December 31, 2014</b>
	(in thousands)	
Raw materials	\$ 3,269	\$ 3,367
Work-in-process	2,875	3,464
Finished products	9,776	9,883
Total inventory	\$ 15,920	\$ 16,714

We held inventory on consignment of \$1.0 and \$0.8 million as of September 30, 2015 and December 31, 2014, respectively.

**4. Acquisition and Divestitures*****Clinical Instruments International, Inc.***

In July 2013, we entered into an asset purchase agreement with Clinical Instruments International, Inc. (Clinical Instruments) to acquire substantially all the assets of Clinical Instruments for \$1.1 million. We paid \$0.9 million at the closing and paid the remaining \$0.2 million in October 2014. We accounted for the acquisition as a business combination. Assets acquired include inventory and intellectual property. We recorded \$0.2 million of inventory, \$0.3 million of intangible assets and \$0.6 million of goodwill. The weighted-average amortization period for the acquired intangible assets as of July 31, 2013 was 5.7 years. The goodwill will be deductible for tax purposes over 15 years.

***InaVein LLC***

In August 2013, we entered into an asset purchase agreement with InaVein LLC (InaVein) to acquire substantially all the assets of InaVein for \$2.5 million and potential acquisition-related contingent consideration totaling up to \$1.4 million in 2014 and 2015 dependent on the sales performance of the acquired business and the timing of regulatory approval in China. We paid \$2.1 million at the closing and paid the remaining \$0.4 million in September 2014. We accounted for the acquisition as a business combination. Assets acquired include receivables, inventory, equipment, and intellectual property. Liabilities assumed include payables and service contracts. We recorded \$0.8 million of tangible assets, \$1.1 million of intangible assets, \$0.7 million of goodwill, and \$0.1 million of assumed liabilities. The weighted-average amortization period for the acquired intangible assets as of August 31, 2013 was 6.7 years. The goodwill will be deductible for tax purposes over 15 years.

The contingent consideration was initially valued at the date of acquisition and is remeasured each reporting period until the contingency is resolved. Based upon stronger than expected sales to China, we recorded an increase of \$0.1 million in the contingent consideration dependent on the sales performance of the acquired business in the first year following the closing as a charge to general and administrative expense in 2014. In October 2014, we paid \$0.2 million for the first sales related milestone. The milestone related to the timing of the regulatory approval in China was not achieved. The final potential milestone payment was dependent on sales performance of the acquired business



from August 2014 to August 2015. This milestone was not achieved.

***Xenotis Pty Ltd***

In August 2014, we entered into a stock purchase agreement with the shareholders of Xenotis Pty Ltd (Xenotis) to acquire all of the capital stock of Xenotis for \$6.7 million based on foreign exchange rates in effect at the time of the closing, with a mechanism for a purchase price adjustment based on the net tangible assets of Xenotis at closing. Xenotis is the parent company of Bio Nova International, the manufacturer and marketer of the Omniflow II biosynthetic vascular graft for lower extremity bypass and AV access. We paid \$5.1 million at the closing with the final payment of \$1.1 million made in August 2015.

**Table of Contents**

The net tangible asset purchase price adjustment of \$0.2 million was paid in November 2014. We accounted for the acquisition as a business combination. Assets acquired include receivables, inventory, equipment, a building, and intellectual property. We recorded \$2.1 million of tangible assets, \$2.1 million of property and equipment, \$1.8 million of intangible assets, and \$2.5 million of goodwill. The weighted-average amortization period for the acquired intangible assets as of August 31, 2014 was 6.8 years. Liabilities assumed include payables and debt which totaled \$1.7 million and included \$1.1 million of assumed debt, which we paid in full in August 2014. The purchase accounting is complete.

The goodwill of \$2.5 million will not be deductible for tax purposes. In addition, we acquired deferred tax assets of \$2.4 million which consist primarily of net operating loss carry-forwards and capital loss carry-forwards. We recorded a full valuation allowance on these deferred tax assets.

In September 2014, we entered into definitive agreements with eight former Xenotis distributors in Europe to terminate their distribution of our Omniflow II biosynthetic vascular grafts for \$1.3 million. We paid approximately \$1.1 million in 2014 and \$0.2 million in 2015 with the remaining approximately \$20,000 due in December 2015. We recorded \$0.4 million of inventory and \$0.9 million of intangible assets. We allocated the payment to the tangible and intangible assets acquired based on the estimated fair value of each of these elements to the transactions. The weighted-average amortization period for the acquired intangible assets as of September 30, 2014 was 5.0 years.

***Tru-Incise Valvulotome***

In May 2015, we entered into an asset purchase agreement with UreSil, LLC (UreSil) to acquire the production and distribution rights of UreSil's Tru-Incise valvulotome for sales outside the United States for \$1.4 million. We paid \$1.1 million with the remaining \$0.3 million payable at various points in 2016 and 2017. We accounted for the acquisition as a business combination. Assets acquired include inventory and intellectual property. We did not assume any liabilities. The purchase accounting is complete.

The following table summarizes the purchase price allocation at the date of the acquisition:

	<b>Allocated Fair Value (in thousands)</b>
Inventory	\$ 88
Intangible assets	545
Goodwill	742
Purchase price	\$ 1,375

The goodwill will be deductible for tax purposes over 15 years.

**Table of Contents**

The following table reflects the allocation of the acquired intangible assets and related estimated useful lives:

	<b>Allocated Fair Value</b>	<b>Weighted Average Useful Life</b>
	(in thousands)	
Non-compete agreement	\$ 120	5.0 years
Tradename license	17	3.0 years
Technology	391	7.0 years
Customer relationships	17	3.0 years
<b>Total intangible assets</b>	<b>\$ 545</b>	

**Other Items**

Following the Tru-Incise valvulotome acquisition, we entered into definitive agreements with seven UreSil distributors to terminate their distribution of the Tru-Incise valvulotome for \$0.2 million. We paid approximately \$0.1 million to date with the remainder primarily due in 2015. We recorded approximately \$0.2 million of intangible assets with a weighted-average amortization period of 3.0 years.

In August 2015, we entered into a definitive agreement with Grex Medical Oy (Grex) our distributor in Finland in order to terminate their distribution of our products and we will begin selling direct to hospitals in Finland as of January 1, 2016. The agreement required us to pay approximately \$0.2 million in exchange for the purchase of customer lists and a non-compete agreement.

Our acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of synergies that will be realized by combining businesses. These synergies include the use of our existing sales channel to expand sales of the acquired businesses' products, consolidation of manufacturing facilities, and the leveraging of our existing administrative infrastructure.

**Non-occlusive Modeling Catheter Divestiture**

In July 2015, we entered into an asset sales agreement with Merit Medical Ireland Limited to sell our inventory, intellectual property, and customer lists associated with our non-occlusive modeling catheter product line for \$0.4 million which was recognized as a gain on divestiture in the three months ended September 30, 2015. During the nine months ended September 30, 2014, we recognized an impairment charge of \$0.2 million on our non-occlusive modeling catheter product line. Additionally, we recognized a \$0.3 million charge to cost of sales related to the non-occlusive modeling catheter inventory.

The fair market valuations associated with these transactions fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long range strategic plans and other estimates.



**Table of Contents****5. Goodwill and Other Intangibles**

Goodwill consists of the following:

	(in thousands)
Balance at beginning of year	\$ 17,281
Additions for acquisitions	742
Effects of currency exchange	(306)
Balance at September 30, 2015	\$ 17,717

Other intangibles consist of the following:

	September 30, 2015			December 31, 2014		
	Gross Carrying Value	Accumulated Amortization	Net Carrying Value	Gross Carrying Value	Accumulated Amortization	Net Carrying Value
	(in thousands)					
Product technology	\$ 7,083	\$ 3,052	\$ 4,031	\$ 7,134	\$ 2,777	\$ 4,357
Trademarks and licenses	1,556	1,190	366	1,557	1,074	483
Customer relationships	3,791	2,054	1,737	3,694	1,781	1,913
Other intangible assets	1,295	773	522	1,084	680	404
Total identifiable intangible assets	\$ 13,725	\$ 7,069	\$ 6,656	\$ 13,469	\$ 6,312	\$ 7,157

These intangible assets are being amortized over their useful lives ranging from 1 to 13 years. The weighted-average amortization period for these intangibles as of September 30, 2015 is 7.3 years. Amortization expense is included in general and administrative expense and is as follows:

	Three months ended		Nine months ended	
	September 30, 2015	2014	September 30, 2015	2014
	(in thousands)			
Amortization expense	\$ 387	\$ 359	\$ 1,135	\$ 1,098

Estimated amortization expense for the remainder of 2015 and each of the five succeeding fiscal years is as follows:

2015	2016	2017	2018	2019	2020
(in thousands)					

Amortization expense	\$ 365	\$ 1,456	\$ 1,199	\$ 1,012	\$ 827	\$ 578
----------------------	--------	----------	----------	----------	--------	--------

**Table of Contents****6. Accrued Expenses**

Accrued expenses consist of the following:

	<b>September 30, 2015</b>	<b>December 31, 2014</b>
	(in thousands)	
Compensation and related taxes	\$ 4,539	\$ 4,819
Income and other taxes	657	444
Professional fees	476	496
Other	1,926	1,720
<b>Total</b>	<b>\$ 7,598</b>	<b>\$ 7,479</b>

**7. Restructuring**

In February 2014, we committed to a plan intended to improve operational efficiencies, which included a reduction in force of approximately 10% of our workforce and other cost-cutting measures, including the transfer of our Clinical Instruments manufacturing to our Burlington headquarters and corresponding closure of our Southbridge manufacturing facility. As a result, we recorded approximately \$0.4 million of severance related restructuring expense for the three months ended March 31, 2014. We made approximately \$0.1 million of severance related payments during the three months ended March 31, 2014.

In April 2014, we committed to an additional reduction in force of approximately seven employees. As a result, we recorded approximately \$0.1 million of severance related restructuring expense for the three months ended June 30, 2014.

We did not incur restructuring charges during the nine months ended September 30, 2015.

**8. Commitments and Contingencies***Purchase Commitments*

As of September 30, 2015, as part of our normal course of business, we have commitments to purchase \$2.5 million of inventory through 2017.

**9. Segment and Enterprise-Wide Disclosures**

The FASB establishes standards for reporting information regarding operating segments in financial statements. Operating segments are identified as components of an enterprise about which separate, discrete financial information is evaluated by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. We view our operations and manage our business as one operating segment. No discrete operating information is prepared by us except for product sales by product line and by legal entity for local reporting purposes.





**Table of Contents**

Most of our revenues were generated in the United States, Germany, Italy, Japan, Canada, and other European countries, and substantially all of our assets are located in the United States. Net sales to unaffiliated customers by country were as follows:

	<b>Three months ended</b>		<b>Nine months ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2015</b>	<b>2014</b>	<b>2015</b>	<b>2014</b>
	(in thousands)			
United States	\$ 11,171	\$ 10,605	\$ 33,774	\$ 31,221
Germany	2,208	1,789	6,900	5,551
Italy	579	635	1,991	1,976
Other countries	5,067	4,472	15,204	13,668
<b>Net Sales</b>	<b>\$ 19,025</b>	<b>\$ 17,501</b>	<b>\$ 57,869</b>	<b>\$ 52,416</b>

**10. Share-based Compensation**

Our 2006 Stock Option and Incentive Plan allows for granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, unrestricted stock awards, and deferred stock awards to our officers, employees, directors, and consultants.

The components of share-based compensation expense were as follows:

	<b>Three months ended</b>		<b>Nine months ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2015</b>	<b>2014</b>	<b>2015</b>	<b>2014</b>
	(in thousands)			
Stock option awards	\$ 327	\$ 294	\$ 752	\$ 687
Restricted stock units	152	145	336	295
<b>Total share-based compensation</b>	<b>\$ 479</b>	<b>\$ 439</b>	<b>\$ 1,088</b>	<b>\$ 982</b>

We have computed the weighted average fair values of employee stock options for option grants issued during the nine months ended September 30, 2015 and 2014 using the Black-Scholes option model with the following assumptions:

	<b>2015</b>	<b>2014</b>
Dividend yield	1.4%	1.8%
Volatility	28.6%	45.2%
Risk-free interest rate	1.8%	2.0%

Weighted average expected option term (in years)	5.6	5.5
Weighted average fair value per share of options granted	\$ 2.80	\$ 2.81

The weighted-average fair value per share of restricted stock unit grants issued for the nine months ended September 30, 2015 was \$11.32. The weighted-average fair value per share of restricted stock unit grants issued for the nine months ended September 30, 2014 was \$7.87.

We issued approximately 721,000 and 175,000 shares of common stock following the exercise or vesting of underlying stock options or restricted stock units in the nine months ended September 30, 2015 and 2014, respectively.

**Table of Contents****11. Net Income per Share**

The computation of basic and diluted net income per share was as follows:

	<b>Three months ended</b>		<b>Nine months ended</b>	
	<b>September 30,</b>	<b>September 30,</b>	<b>September 30,</b>	<b>September 30,</b>
	<b>2015</b>	<b>2014</b>	<b>2015</b>	<b>2014</b>
	(in thousands, except per share data)			
<b>Basic:</b>				
Net income available for common stockholders	\$ 2,092	\$ 934	\$ 5,228	\$ 1,999
Weighted average shares outstanding	17,865	17,348	17,625	16,358
Basic earnings per share	\$ 0.12	\$ 0.05	\$ 0.30	\$ 0.12
<b>Diluted:</b>				
Net income available for common stockholders	\$ 2,092	\$ 934	\$ 5,228	\$ 1,999
Weighted-average shares outstanding	17,865	17,348	17,625	16,358
Common stock equivalents, if diluted	632	361	510	414
Shares used in computing diluted earnings per common share	18,497	17,709	18,136	16,772
Diluted earnings per share	\$ 0.11	\$ 0.05	\$ 0.29	\$ 0.12
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive	40	356	81	228

**12. Stockholders Equity****Share Offering**

On June 4, 2014, we issued 1,644,500 shares of our common stock, \$0.01 par value per share, at a price to the public of \$7.00 per share less underwriting discounts. The net proceeds, after deducting the underwriting discounts and other estimated offering expenses, were approximately \$10.5 million. We deployed the net proceeds from the offering on acquisitions consummated in 2014 and used the remainder for general corporate purposes, including continued development of our products, working capital and capital expenditures, payments under our quarterly dividend program, and payments related to acquisitions.

**Table of Contents****Dividends**

In February 2011, our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:

<b>Record Date</b>	<b>Payment Date</b>	<b>Per Share Amount</b>	<b>Dividend Payment</b> (in thousands)
<b>Fiscal Year 2015</b>			
March 20, 2015	April 3, 2015	\$ 0.040	\$ 700
May 22, 2015	June 5, 2015	\$ 0.040	\$ 705
August 20, 2015	September 3, 2015	\$ 0.040	\$ 715
<b>Fiscal Year 2014</b>			
March 20, 2014	April 3, 2014	\$ 0.035	\$ 546
May 22, 2014	June 5, 2014	\$ 0.035	\$ 547
August 21, 2014	September 4, 2014	\$ 0.035	\$ 607
November 20, 2014	December 4, 2014	\$ 0.035	\$ 608

On October 22, 2015 our Board of Directors approved a quarterly cash dividend on our common stock of \$0.04 per share payable on December 4, 2015 to stockholders of record at the close of business on November 20, 2015, which will total approximately \$0.7 million.

**13. Supplemental Cash Flow Information**

	<b>Nine months ended</b>	
	<b>September 30, 2015</b>	<b>September 30, 2014</b>
	(in thousands)	
Cash paid for income taxes, net	\$ 3,341	\$ 1,276
Common stock repurchased for RSU tax withholdings	\$ 266	\$ 211

**14. Fair Value Measurements**

The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1 Quoted prices in active markets for identical assets or liabilities.

Level 2 Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

As of September 30, 2015, we had cash equivalents in a money market fund that was valued using Level 1 inputs (quoted market prices for identical assets) at a fair value of \$12.0 million.

We had no Level 2 assets being measured at fair value on a recurring basis as of September 30, 2015.

As discussed in Note 4, we had one remaining acquisition-related contingent liability which is remeasured each reporting period using Level 3 techniques based on an assessment of the probability that we will be required to make such future payment. There were no changes in estimated liability associated with this milestone as we were not required to pay the second sales related milestone.

---

**Table of Contents****15. Accumulated Other Comprehensive Loss**

Changes to our accumulated other comprehensive loss consisted of foreign currency translation for the nine months ended September 30, 2015 and 2014, respectively.

	<b>Nine months ended</b>	
	<b>September 30,</b>	
	<b>2015</b>	<b>2014</b>
Beginning balance	\$ (2,365)	\$ (253)
Other comprehensive loss before reclassifications	(1,668)	(1,375)
Ending Balance	\$ (4,033)	\$ (1,628)

---

**Table of Contents****Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*This Quarterly Report on Form 10-Q contains forward-looking statements (within the meaning of the federal securities law) that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, future financial position, future net sales, projected costs, projected expenses, prospects and plans and objectives of management are forward-looking statements. The words anticipates, believes, estimates, expects, intends, may, plans, projects, will, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying any of our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections, or expectations prove incorrect, our actual results, performance, or financial condition may vary materially and adversely from those anticipated, estimated, or expected. These risks and uncertainties include, but are not limited to: the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the risk that assumptions about the market for the Company's products and the productivity of the Company's direct sales force and distributors may not be correct; risks related to product demand and market acceptance of the Company's products and pricing; the risk that the introduction of the HYDRO valvulotome will not be well received in the marketplace; risks related to attracting, training and retaining sales representatives and other employees in new markets such as Finland and New Zealand; adverse or fluctuating conditions in the general domestic and global economic markets; and the risk that the Company is not successful in transitioning to a direct-selling model in new territories.*

*Forward-looking statements reflect management's analysis as of the date of this quarterly report. Further information on potential risk factors that could affect our business and financial results is detailed in Part II, Item 1A, Risk Factors in this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission, including under the section headed Risk Factors in our most recent Annual Report on Form 10-K. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes included in this report and our other SEC filings, including our audited consolidated financial statements and the related notes contained in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC on March 18, 2015. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.*

*Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us in this Quarterly Report on Form 10-Q refer to LeMaitre Vascular, Inc. and its subsidiaries.*

*LeMaitre, AlboSure, Omniflow, and XenoSure are registered trademarks of LeMaitre Vascular or one of its subsidiaries. This Quarterly Report on Form 10-Q also includes the registered and unregistered trademarks of other persons, which are the property of their respective owners.*

**Overview**

We are a medical device company that develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease. Our principal product offerings are sold throughout the world, primarily in North America, Europe and, to a lesser extent, Asia and the Pacific Rim. We estimate that the annual worldwide market for all peripheral vascular devices approximates \$4 billion, within which our core product lines address

roughly \$750 million. We have grown our business by using a three-pronged strategy: competing for sales of niche products, expanding our worldwide direct sales force, and acquiring and developing complementary vascular devices. We have used acquisitions as a primary means of further accessing the larger peripheral vascular device market, and we expect to continue to pursue this strategy in the future. Additionally, we have increased our efforts to expand our vascular device offerings through new product development. We currently manufacture most of our product lines in our Burlington, Massachusetts headquarters.



## Table of Contents

Our products are used by vascular surgeons who treat peripheral vascular disease through both open surgical methods and endovascular techniques. In contrast to interventional cardiologists and interventional radiologists, neither of whom are certified to perform open surgical procedures, vascular surgeons can perform both open surgical and minimally invasive endovascular procedures, and are therefore uniquely positioned to provide a wider range of treatment options to patients.

Our principal product lines include the following: valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, biosynthetic vascular grafts, angioscopes, and powered phlebectomy devices.

To assist us in evaluating our business strategies, we regularly monitor long-term technology trends in the peripheral vascular device market. Additionally, we consider the information obtained from discussions with the medical community in connection with the demand for our products, including potential new product launches. We also use this information to help determine our competitive position in the peripheral vascular device market and our manufacturing capacity requirements.

Our business opportunities include the following:

the long-term growth of our sales force in North America, Europe, Asia and the Pacific Rim, sometimes in connection with terminations of certain distributor relationships in order to expand our sales presence in new countries;

the addition of complementary products through acquisitions;

the updating of existing products and introduction of new products through research and development;

the introduction of our products in new territories upon receipt of regulatory approvals in these territories; and

the consolidation of product manufacturing into our Burlington, Massachusetts corporate headquarters facility.

We sell our products primarily through a direct sales force. As of September 30, 2015, our sales force was comprised of 82 sales representatives in North America, Europe, Japan, Australia, and New Zealand. We also sell our products in other countries through distributors. Our worldwide headquarters is located in Burlington, Massachusetts. Our international operations are headquartered in Sulzbach, Germany. We also have sales offices located in Tokyo, Japan; Mississauga, Canada; Madrid, Spain; Milan, Italy; Shanghai, China; and North Melbourne, Australia. In the nine months ended September 30, 2015, approximately 93% of our net sales were generated in territories in which we employ direct sales representatives.

We have experienced success in niche product segments, for example the market segments for biologic patches and valvulotome devices. In the biologic patch market segment, we believe that we have been able to increase segment share and increase selling prices. In the valvulotome market segment, we believe that we have been able to increase

selling prices without significantly compromising market segment share. There can be no assurance that we will not meet resistance to increased selling prices in the future, particularly with respect to the recent introduction of our HYDRO valvulotome. In contrast, we have experienced less success in highly competitive product segments such as polyester and ePTFE grafts, where we face stronger competition from larger companies with greater resources. We have also experienced less success in segments such as radiopaque tape, where we face recently introduced competitive products. While we believe that these challenging market dynamics can be mitigated by our strong relationships with our vascular surgeon customers, there can be no assurance that we will be successful in highly competitive market segments or market segments or geographies where there is pricing sensitivity.

## **Table of Contents**

In recent years we have also experienced comparatively greater success in geographic markets outside of the United States, including Europe and other non-traditional markets for our devices such as China and Saudi Arabia. Sales to these geographies generally include comparatively lower average selling prices, and to the extent that we continue to be successful in these markets which carry a lower margin, we will likely experience downward pressure on our gross margin.

Because we believe that direct-to-hospital sales engender closer customer relationships, and allow for higher selling prices and gross margins, we periodically enter into transactions with our distributors to transition their sales of our medical devices to our direct sales organization:

In 2014, we entered into definitive agreements with eight former Xenotis distributors in Europe in order to terminate their distribution of our Omniflow II biosynthetic vascular grafts and begin selling direct to hospitals in those geographies. The agreements required us to pay approximately \$1.3 million in exchange for the purchase of customer lists and inventory.

In 2015, we entered into definitive agreements with seven UreSil, LLC (UreSil) distributors in Europe in order to terminate their distribution of our newly acquired valvulotome and begin selling direct to hospitals in those geographies. The agreements required us to pay approximately \$0.2 million in exchange for the purchase of customer lists and inventory.

In August 2015, we entered into a definitive agreement with Grex Medical Oy (Grex) our distributor in Finland in order to terminate their distribution of our products and begin selling direct to hospitals in Finland as of January 1, 2016. The agreement required us to pay approximately \$0.2 million in exchange for the purchase of customer lists and a non-compete agreement.

Our strategy for growing our business includes the acquisition of complementary product lines and companies and occasionally the discontinuance or divestiture of products or activities that are no longer complementary:

In August 2014, we acquired all of the capital stock of Xenotis Pty Ltd (Xenotis) for \$6.7 million plus the assumption of \$1.1 million of debt. Xenotis is the parent company of Bio Nova International, the manufacturer and marketer of the Omniflow II biosynthetic vascular graft for lower extremity bypass and AV access.

In September 2014, we acquired substantially all of the assets related to the angioscope product line from Applied Medical Resource Corporation (Applied Medical) for \$0.4 million.

In September 2014, we terminated our non-occlusive modeling catheter product line. In July 2015, we entered into an asset sales agreement with Merit Medical Ireland Limited to sell our inventory, intellectual property, and customer lists associated with the non-occlusive modeling catheter product line for \$0.4 million.

In May 2015, we acquired the production and distribution rights of UreSil's Tru-Incise valvulotome for sales outside the United States for \$1.4 million.

As of December 31, 2015 we will terminate our InvisiGrip vein stripper product line, and we wrote down \$0.1 million of related inventory in the third quarter of 2015.

In addition to relying upon acquisitions to grow our business, we also rely on our product development efforts to bring differentiated technology and next-generation products to market. These efforts have led to the following recent product developments:

In May 2013, we launched the 1.5mm Expandable LeMaitre Valvulotome.

In June 2013, we launched the AlboSure Vascular Patch.

In June 2014, we launched the 1.5mm HYDRO LeMaitre Valvulotome.

## **Table of Contents**

In addition to our sales growth strategies, we have also executed several operational initiatives designed to consolidate and streamline manufacturing within our Burlington, Massachusetts facilities. We expect that these plant consolidations will result in improved control over our production capacity as well as reduced costs over the long-term. Our most recent manufacturing transitions included:

In January 2014, we initiated a project to transfer the manufacturing of the Clinical Instruments devices to our facility in Burlington. We closed the Clinical Instruments facility in March and completed the manufacturing transfer during the second quarter of 2014.

In March 2015, we initiated the transfer of the manufacturing of our newly acquired angioscope product line to our facility in Burlington. We have been purchasing the devices from Applied Medical since the acquisition. We expect the manufacturing transfer to be complete by December 2015.

In May 2015, we initiated plans to establish a production line for our newly acquired Tru-Incise valvulotome product line in our facility in Burlington. We have been purchasing the devices from UreSil since the acquisition. We expect the establishment of the production line to be complete by March 2016.

We currently expect to maintain the manufacturing operations of the recently acquired North Melbourne, Australia facility for the foreseeable future.

Our execution of these business opportunities may affect the comparability of our financial results from period to period and may cause substantial fluctuations from period to period, as we incur related restructuring and other non-recurring charges, as well as longer term impacts to revenues and operating expenditures. For example, in 2014, we incurred \$0.5 million of restructuring charges related to reductions in force and our Clinical Instruments facility closure and relocation to Burlington, Massachusetts.

Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies, primarily the Euro, affect our financial results. For the nine months ended September 30, 2015, approximately 42% of our sales were from outside the United States. We expect that foreign currencies will continue to represent a similarly significant percentage of our sales in the future. Selling, marketing, and administrative costs related to these sales are largely denominated in the same respective currency, thereby partially mitigating our transaction risk exposure. However, most of our foreign sales are denominated in local currency, and if there is an increase in the rate at which a foreign currency is exchanged for U.S. dollars, it will require more of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In such cases we will receive less in U.S. dollars than we did before the rate increase went into effect. For the nine months ended September 30, 2015, the negative effects of foreign exchange reduced sales by \$4.5 million. As of October 27, 2015, we estimate that the strong U.S. dollar could decrease our 2015 revenues by approximately \$5.1 million, reduce gross margin by 1.6%, and reduce operating income by approximately \$2.4 million as compared to the exchange rates for the year ended December 31, 2014. However, the actual impact of fluctuations in exchange rates in 2015 may vary materially and adversely from these estimates.

## **Net Sales and Expense Components**

The following is a description of the primary components of our net sales and expenses:

**Net sales.** We derive our net sales from the sale of our products, less discounts and returns. Net sales include the shipping and handling fees paid for by our customers. Most of our sales are generated by our direct sales force and are shipped and billed to hospitals or clinics throughout the world. In countries where we do not have a direct sales force, sales are primarily generated by shipments to distributors who, in turn, sell to hospitals and clinics. In those cases where our products are held on consignment at a hospital or clinic, we generate sales at the time the product is used in surgery rather than at shipment.

**Cost of sales.** We manufacture nearly all of the products that we sell. Our cost of sales consists primarily of manufacturing personnel, raw materials and components, depreciation of property and equipment, and other allocated manufacturing overhead, as well as freight expense we pay to ship products to customers.

**Sales and marketing.** Our sales and marketing expense consists primarily of salaries, commissions, stock based compensation, travel and entertainment, attendance at medical society meetings, training programs, advertising and product promotions, direct mail, and other marketing costs.

**Table of Contents**

**General and administrative.** General and administrative expense consists primarily of executive, finance and human resource expense, stock based compensation, legal and accounting fees, information technology expense, intangible amortization expense, and insurance expense.

**Research and development.** Research and development expense includes costs associated with the design, development, testing, enhancement, and regulatory approval of our products, principally salaries, laboratory testing, and supply costs. It also includes costs associated with design and execution of clinical studies, regulatory submissions and costs to register, maintain, and defend our intellectual property, and royalty payments associated with licensed and acquired intellectual property.

**Restructuring.** Restructuring expense includes costs directly associated with distribution agreement termination expenses, severance and retention costs for terminated employees, factory relocation costs, and other expenses associated with restructuring our operations.

**Other income (expense).** Other income (expense) primarily includes interest income and expense, foreign currency gains (losses), and other miscellaneous gains (losses).

**Income tax expense.** We are subject to federal and state income taxes for earnings generated in the United States, which include operating losses in certain foreign jurisdictions for certain years depending on tax elections made, and foreign taxes on earnings of our wholly-owned Canadian, German, Italian, and Chinese subsidiaries. Our consolidated tax expense is affected by the mix of our taxable income (loss) in the United States and foreign subsidiaries, permanent items, discrete items, unrecognized tax benefits, and amortization of goodwill for U.S tax reporting purposes.

**Results of Operations****Comparison of the three and nine months ended September 30, 2015 to the three and nine months ended September 30, 2014.**

The following tables set forth, for the periods indicated, our results of operations, net sales by geography, and the change between the specified periods expressed as a percentage increase or decrease:

(unaudited)	Three months ended September 30,			Nine months ended September 30,		
	2015	2014	Percent change (\$ in thousands)	2015	2014	Percent change
Net sales	\$ 19,025	\$ 17,501	9%	\$ 57,869	\$ 52,416	10%
Net sales by geography:						
Americas	\$ 11,916	\$ 11,102	7%	\$ 35,870	\$ 32,566	10%
International	7,109	6,399	11%	21,999	19,850	11%
Total	\$ 19,025	\$ 17,501	9%	\$ 57,869	\$ 52,416	10%

**Net sales.** Net sales increased 9% to \$19.0 million for the three months ended September 30, 2015, compared to \$17.5 million for the three months ended September 30, 2014. Sales increases for the three months ended September 30, 2015 were primarily driven by increased sales of our biologic vascular patches of \$0.9 million, biosynthetic vascular grafts of \$0.8 million and valvulotomes of \$0.2 million, and were partially offset by decreased sales of shunts of \$0.3 million and catheters of \$0.2 million, and the negative effects of changes in foreign currency exchange rates of \$1.3 million. The recent introduction of the higher priced HYDRO LeMaitre Valvulotome in 2014 in the United States and in 2015 outside the United States, may adversely impact unit sales going forward.



**Table of Contents**

Net sales increased 10% to \$57.9 million for the nine months ended September 30, 2015, compared to \$52.4 million for the nine months ended September 30, 2014. Sales increases for the nine months ended September 30, 2015 were primarily driven by increased sales of our biosynthetic vascular grafts of \$2.8 million, biologic vascular patches of \$2.1 million, and valvulotomes of \$1.3 million (driven by the HYDRO LeMaitre Valvulotome conversion), and were partially offset by decreased sales of embolectomy catheters of \$0.6 million, and cholangiogram catheters of \$0.3 million, and the negative effects of changes in foreign currency exchange rates of \$4.5 million.

Direct-to-hospital net sales were 93% for the nine months ended September 30, 2015, versus 92% for the nine months ended September 30, 2014.

**Net sales by geography.** Net sales in the Americas increased \$0.8 million for the three months ended September 30, 2015. The increase was primarily driven by biologic vascular patches, vessel closure systems and radiopaque tape, and was partially offset by decreased sales of shunts and occlusion catheters. International net sales increased \$0.7 million for the three months ended September 30, 2015. The increase was primarily driven by sales of our newly acquired biosynthetic vascular graft, increased sales in biologic vascular patches and valvulotomes, and was partially offset by decreased sales of vessel closure systems and shunts.

Net sales in the Americas increased \$3.3 million for the nine months ended September 30, 2015. The increase was primarily driven by biologic vascular patches, valvulotomes, and radiopaque tape, and was partially offset by decreased sales of cholangiogram catheters, occlusion catheters, and remote endarterectomy devices. International net sales increased \$2.1 million for the nine months ended September 30, 2015. The increase was primarily driven by sales of our newly acquired biosynthetic vascular graft, biologic vascular patches and valvulotomes, and was partially offset by decreased sales of radiopaque tape.

(unaudited)	Three months ended September 30,				Nine months ended September 30,			
	2015	2014	\$ Change	Percent change	2015	2014	\$ Change	Percent change
	(\$ in thousands)							
Gross profit	\$ 13,516	\$ 12,003	\$ 1,513	13%	\$ 39,763	\$ 35,603	\$ 4,160	12%
Gross margin	71.0%	68.6%	*	2.4%	68.7%	67.9%	*	0.8%
* Not applicable								

**Gross Profit.** Gross profit increased \$1.5 million to \$13.5 million for the three months ended September 30, 2015, while gross margin increased 2.4% to 71.0% in the period. The gross margin increase was largely driven by improved manufacturing efficiencies related to biologic vascular patches and prosthetic grafts, and average selling price increases, which were partially offset by the negative impact of changes in foreign currency exchange rates on our international sales, unfavorable geographic mix, and the write-off of inventory related to the discontinuation of our InvisiGrip vein stripper. The gross profit increase was a result of higher sales and a higher gross margin.

Gross profit increased \$4.2 million to \$39.8 million for the nine months ended September 30, 2015, while gross margin increased to 68.7% in the period. The gross margin was favorably impacted by the completion of the biologic vascular patch manufacturing transition in the first half of 2014 resulting in reduced manufacturing costs in the current year, other manufacturing efficiencies, and by higher average selling prices across nearly all product lines. These increases were partially offset by the negative impact of changes in foreign currency exchange rates on our international sales and unfavorable geographic mix. The gross profit increase was a result of higher sales and a higher gross margin.



**Table of Contents**

(unaudited)	Three months ended September 30,				Nine months ended September 30,			
	2015	2014	\$ Change	Percent change	2015	2014	\$ Change	Percent change
	(\$ in thousands)							
Sales and marketing	\$ 5,489	\$ 5,091	\$ 398	8%	\$ 16,866	\$ 16,857	\$ 9	0%
General and administrative	3,455	3,765	(310)	(8%)	10,375	10,376	(1)	0%
Research and development	1,421	1,109	312	28%	3,904	3,590	314	9%
Medical device excise tax	190	178	12	7%	554	518	36	7%
Restructuring charges		8	(8)	*		500	(500)	*
Impairment charges				*		161	(161)	*
Gain on divestiture	(360)		(360)	*	(360)		(360)	*
Total	\$ 10,195	\$ 10,151	\$ 44	0%	\$ 31,339	\$ 32,002	\$ (663)	(2%)

	Three months ended September 30,			Nine months ended September 30,		
	2015 %	2014 %	Change	2015 %	2014 %	Change
Sales and marketing	29%	29%	0%	29%	32%	(3%)
General and administrative	18%	22%	4%	18%	20%	(2%)
Research and development	7%	6%	1%	7%	7%	0%
Medical device excise tax	1%	1%	0%	1%	1%	0%
Restructuring charges	0%	0%	0%	0%	1%	(1%)
Impairment charges	0%	0%	0%	0%	0%	0%
Gain on divestiture	(2%)	0%	(2%)	(1%)	0%	(1%)

\* Not a meaningful percentage relationship.

**Sales and marketing.** For the three months ended September 30, 2015, sales and marketing expense increased \$0.4 million to \$5.5 million. The increase was driven primarily by increased sales compensation, commission, recruiting and travel and entertainment expenses, which were partially offset by changes in foreign currency exchange rates of \$0.4 million.

For the nine months ended September 30, 2015, sales and marketing expenses were flat at \$16.9 million. Changes in foreign currency exchange rates decreased expenses by \$1.4 million and were offset by increased sales meetings and recruiting costs. As a percentage of net sales, sales and marketing expense were 29% in the nine months ended September 30, 2015. We plan to increase the size of our sales force in the fourth quarter of 2015, and we expect that selling and marketing expenses will increase commensurately.

**General and administrative.** For the three months ended September 30, 2015, general and administrative expenses decreased \$0.3 million to \$3.5 million. The decrease was driven by higher acquisition related costs in the prior year related to the Xenotis and AngioScope acquisitions, as well as the effects of changes in foreign currency exchange rates of \$0.2 million.

For the nine months ended September 30, 2015, general and administrative expense were flat at \$10.4 million. General and administrative expense were driven by higher compensation and recruiting costs, which were offset by lower acquisition costs and changes in foreign currency exchange rates of \$0.5 million. Contingent

consideration expense related to the InaVein acquisition of \$0.2 million was incurred in 2014. As a percentage of net sales, general and administrative expense was 18% in the nine months ended September 30, 2015. We expect general and administrative expenses to increase in 2015 in part due to an increase in personnel in our China and Australia subsidiaries.

**Research and development.** For the three months ended September 30, 2015, research and development expense increased \$0.3 million to \$1.4 million. Product development expenses increased \$0.1 million primarily driven by product testing costs, process engineering costs increased \$0.1 million largely due to the manufacturing transfer of the AngioScope and Tru-Incise product lines to our Burlington facility, and clinical and regulatory expenses were flat. The effects of changes in foreign currency exchange rates were minimal.

For the nine months ended September 30, 2015, research and development expenses increased \$0.3 million to \$3.9 million. Product development expenses increased \$0.2 million primarily driven by product testing costs, process engineering increased \$0.2 million largely due to the manufacturing transfer of the AngioScope and Tru-

---

**Table of Contents**

Incise product lines to our Burlington facility, and clinical and regulatory expenses decreased \$0.1 million primarily due to costs related to regulatory submissions for new products in geographies such as China and Australia completed in 2014. The effects of changes in foreign currency exchange rates were minimal.

**Restructuring.** In February 2014, we committed to a plan intended to improve operational efficiencies, which included a reduction in force of approximately 10% of our workforce and other cost-cutting measures, including the transfer of our recently acquired Clinical Instruments manufacturing to our Burlington headquarters and corresponding closure of our Southbridge manufacturing facility. As a result, we recorded approximately \$0.4 million of severance related restructuring expense for the three months ended March 31, 2014. In April 2014, we committed to an additional reduction in force of approximately seven employees. As a result, we recorded approximately \$0.1 million of severance related restructuring expense for the three months ended June 30, 2014. We did not incur restructuring charges during the nine months ended September 30, 2015.

**Impairment charges.** During the nine months ended September 30, 2014, we recognized an intangible asset impairment charge of \$0.2 million upon the termination of our non-occlusive modeling catheter product line. We did not incur impairment charges during the nine months ended September 30, 2015.

**Gain on Divestiture.** In July 2015, we entered into an asset sales agreement with Merit Medical Ireland Limited to sell our inventory, intellectual property, and customer lists associated with our non-occlusive modeling catheter product line for \$0.4 million which was recognized as a gain on divestiture in the three months ended September 30, 2015.

**Medical device excise tax.** The medical device excise tax was relatively flat for the three months and nine months ended September 30, 2015 and 2014, respectively.

**Income tax expense.** We recorded a provision for taxes of \$1.0 million on pre-tax income of \$3.1 million for the three months ended September 30, 2015, compared to \$1.0 million on pre-tax income of \$1.9 million for the three months ended September 30, 2014. We recorded a provision for taxes of \$3.1 million on pre-tax income of \$8.3 million for the nine months ended September 30, 2015, compared to \$1.6 million on pre-tax income of \$3.6 million for the nine months ended September 30, 2014. Our 2015 provision was based on the estimated annual effective tax rate of 36.3%, comprised of estimated federal and state income taxes of approximately \$3.8 million, as well as foreign income taxes of \$0.3 million. Our income tax expense for the current period varies from the statutory rate amounts mainly due to certain permanent items, offset by lower statutory rates from our foreign entities and a discrete item for stock option exercises. Our 2014 provision was based on the estimated annual effective tax rate of 38.7%, comprised of estimated federal and state income taxes of approximately \$2.4 million, as well as foreign income taxes of \$0.3 million. Our 2014 income tax expense varied from the statutory rate amounts mainly due to certain permanent items, offset by lower statutory rates from our foreign entities, and discrete items related to certain foreign branch losses previously not deductible and the release of a valuation allowance on certain foreign loss carryforwards. We monitor the mix of profitability by tax jurisdiction and adjust our annual expected rate on a quarterly basis as needed. While it is often difficult to predict the final outcome or timing of the resolution for any particular tax matter, we believe that our tax reserves reflect the probable outcome of known contingencies.

We have assessed the need for a valuation allowance against our deferred tax assets and concluded that as of September 30, 2015, we carried a valuation allowance against \$3.2 million of deferred tax assets, principally foreign net operating loss and capital loss carry-forwards and state research and development credit carry-forwards, which based on the available evidence, we believe it is more likely than not that such assets will not be realized.

Our effective tax rate for 2015 assumes that the Federal research and development tax credit will not be reinstated for 2015. If legislation is enacted to reinstate the Federal research and development tax credit for 2015, then we expect

our effective tax rate will be similar to our effective tax rate in 2014.

### **Liquidity and Capital Resources**

At September 30, 2015, our cash and cash equivalents were \$23.6 million as compared to \$18.7 million at December 31, 2014. Our cash and cash equivalents are highly liquid investments with maturities of 90 days or less at the date of purchase, consist of money market funds, and are stated at cost, which approximates fair value. All of our cash held outside of the United States is available for corporate use.

**Table of Contents**

***Operating and Capital Expenditure Requirements***

We require cash to pay our operating expenses, make capital expenditures, and pay our long-term liabilities. Since our inception, we have funded our operations through public offerings and private placements of equity securities, short-term borrowings, and funds generated from our operations.

We recognized income from operations of \$8.4 million for the nine months ended September 30, 2015. For the year ended December 31, 2014, we recognized income from operations of \$6.3 million. We expect to fund any increased costs and expenditures from our existing cash and cash equivalents, though our future capital requirements depend on numerous factors. These factors include, but are not limited to, the following:

the revenues generated by sales of our products;

payments associated with potential future quarterly cash dividends to our common stockholders;

future acquisition related payments;

payments associated with U.S income and other taxes, such as the medical device tax;

the costs associated with expanding our manufacturing, marketing, sales, and distribution efforts;

the costs associated with our initiatives to sell direct-to-hospital in new countries;

the costs of obtaining and maintaining FDA and other regulatory clearances of our existing and future products; and

the number, timing, and nature of acquisitions and other strategic transactions.

Our cash balances may decrease as we continue to use cash to fund our operations, make acquisitions, make payments under our quarterly dividend program, and make deferred payments related to prior acquisitions. We believe that our cash, cash equivalents, investments and the interest we earn on these balances will be sufficient to meet our anticipated cash requirements for at least the next twelve months. If these sources of cash are insufficient to satisfy our liquidity requirements beyond the next twelve months, we may seek to sell additional equity or debt securities or borrow funds from, or establish a revolving credit facility, with a financial institution. The sale of additional equity and debt securities may result in dilution to our stockholders. If we raise additional funds through the issuance of debt securities, such securities could have rights senior to those of our common stock and could contain covenants that would restrict our operations and possibly our ability to pay dividends. We may require additional capital beyond our currently forecasted amounts. Any such required additional capital may not be available on reasonable terms, if at all.

***Share Offering***

On June 4, 2014, we issued 1,644,500 shares of our common stock, \$0.01 par value per share, at a price to the public of \$7.00 per share less underwriting discounts. The net proceeds, after deducting the underwriting discounts and other estimated offering expenses, were approximately \$10.5 million. We deployed the net proceeds from the offering on acquisitions consummated in 2014 and used the remainder for general corporate purposes, including continued development of our products, working capital and capital expenditures, payments under our quarterly dividend program, and payments related to acquisitions.



**Table of Contents****Dividends**

In February 2011, our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:

<b>Record Date</b>	<b>Payment Date</b>	<b>Per Share Amount</b>	<b>Dividend Payment</b> (in thousands)
<b>Fiscal Year 2015</b>			
March 20, 2015	April 3, 2015	\$ 0.040	\$ 700
May 22, 2015	June 5, 2015	\$ 0.040	\$ 705
August 20, 2015	September 3, 2015	\$ 0.040	\$ 715
<b>Fiscal Year 2014</b>			
March 20, 2014	April 3, 2014	\$ 0.035	\$ 546
May 22, 2014	June 5, 2014	\$ 0.035	\$ 547
August 21, 2014	September 4, 2014	\$ 0.035	\$ 607
November 20, 2014	December 4, 2014	\$ 0.035	\$ 608

On October 22, 2015 our Board of Directors approved a quarterly cash dividend on our common stock of \$0.04 per share payable on December 4, 2015 to stockholders of record at the close of business on November 20, 2015, which will total approximately \$0.7 million.

**Cash Flows**

	<b>Nine months ended September 30,</b> (in thousands)		
	<b>2015</b>	<b>2014</b>	<b>Net Change</b>
Cash and cash equivalents	\$ 23,629	\$ 18,354	\$ 5,275
Cash flows provided by (used in):			
Operating activities	\$ 7,513	\$ 2,830	\$ 4,683
Investing activities	(2,615)	(6,360)	3,745
Financing activities	232	7,452	(7,220)

**Net cash provided by operating activities.** Net cash provided by operating activities was \$7.5 million for the nine months ended September 30, 2015, and consisted of \$5.2 million net income, adjusted for non-cash items of \$4.2 million (including depreciation and amortization of \$2.5 million, stock-based compensation of \$1.1 million, and provision for inventory write-offs of \$0.5 million) and was offset by changes in working capital of \$1.7 million. The net cash used by changes in working capital was driven by increases in accounts receivable of \$1.1 million and prepaid expenses and other assets of \$0.8 million, and was partially offset by increases in accounts payable and other liabilities of \$0.2 million.

Net cash provided by operating activities was \$2.8 million for the nine months ended September 30, 2014, and consisted of a \$2.0 million net income, adjusted for non-cash items of \$4.2 million (including depreciation and amortization of \$2.4 million, stock-based compensation of \$1.0 million, provision for inventory write-offs of \$0.5 million, impairment charges of \$0.2 million, and increases in accrued contingent consideration of \$0.1 million) and was offset by changes in working capital of \$3.4 million. The net cash used by changes in working capital was driven by increases in inventory of \$2.5 million, primarily related to powered phlebectomy devices and biologic vascular patches and accounts receivable of \$0.2 million, and decreases in accounts payable and other liabilities of \$0.3 million.

***Net cash used in investing activities.*** Net cash used in investing activities was \$2.6 million for the nine months ended September 30, 2015. This use of cash was driven by the Tru-Incise acquisition and related distributor buyouts of \$1.3 million, and purchases of property and equipment of \$1.6 million, partially offset by proceeds from the sale of the UnBalloon modeling catheter assets of \$0.4 million.

**Table of Contents**

Net cash used in investing activities was \$6.4 million for the nine months ended September 30, 2014. This was driven by acquisition related payments of \$5.6 million, primarily to Xenotis and Applied Medical, and the purchase of property and equipment of \$0.8 million.

**Net cash used in financing activities.** Net cash provided by financing activities was \$0.2 million for the nine months ended September 30, 2015, driven primarily by proceeds from stock option exercises of \$3.7 million, offset by payments of common stock dividends of \$2.1 million and deferred payments related to the Xenotis acquisition of \$1.1 million.

Net cash provided by financing activities was \$7.5 million for the nine months ended September 30, 2014, driven primarily by proceeds from our secondary stock offering of \$10.5 million and proceeds from stock option exercises of \$0.3 million and partially offset by payments of common stock dividends of \$1.7 million, payment of the debt assumed in the Xenotis acquisition of \$1.1 million, and deferred acquisition payments of \$0.4 million.

**Contractual obligations.** Our principal contractual obligations consist of operating leases and inventory purchase commitments. The following table summarizes our commitments to settle contractual obligations as of September 30, 2015:

Contractual obligations	Total	Less	1-3	3-5	More
		than 1	years	years	than 5
		year			years
			(in thousands)		
Operating leases	\$ 7,203	\$ 1,214	\$ 1,677	\$ 1,684	\$ 2,628
Purchase commitments for inventory	2,515	2,422	92		
<b>Total contractual obligations</b>	<b>\$ 9,718</b>	<b>\$ 3,636</b>	<b>\$ 1,769</b>	<b>\$ 1,684</b>	<b>\$ 2,628</b>

The commitments under our operating leases consist primarily of lease payments for our facilities in North America, Europe, Asia, and Australia. They also include automobile and equipment leases.

The purchase commitments for inventory are intended to be used in operations in the normal course of business and do not represent excess commitments or loss contracts.

**Off-Balance Sheet Arrangements**

We did not have any off-balance sheet arrangements as of September 30, 2015. We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. As a result, we are not materially exposed to any financing, liquidity, market, or credit risk that could arise if we had engaged in these relationships.

**Critical Accounting Policies and Estimates**

We have adopted various accounting policies to prepare our consolidated financial statements in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. Our most significant accounting policies are described in

note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014. There have been no material changes in our critical accounting policies during the nine months ended September 30, 2015. The preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are reviewed on an ongoing basis and updated as appropriate. Actual results may differ from those estimates.

## **Table of Contents**

### ***Recent Accounting Pronouncements***

In May 2014, the Financial Accounting Standards Board issued a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in GAAP. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This standard will be effective for annual reporting periods beginning after December 15, 2017, allows for either full retrospective or modified retrospective application, and early adoption is not permitted. We are assessing the new standard and which adoption method we will apply. We have not yet determined the impact on our results of operations.

### **Item 3.**

#### **Quantitative and Qualitative Disclosures About Market Risk**

This item is not applicable to us as a smaller reporting company.

### **Item 4. Controls and Procedures**

#### **Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Securities Exchange Act of 1934 is reported, processed, and summarized within the time periods specified in the SEC's rules and forms. As of September 30, 2015, or the Evaluation Date, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures were effective at the reasonable assurance level.

#### **Changes in Internal Control**

There have been no changes in our internal control over financial reporting for the quarter ended September 30, 2015, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

#### **Inherent Limitations of Internal Controls**

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions, or the degree of

compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

**Table of Contents****Part II. Other Information****Item 1. Legal Proceedings.**

In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to employment, product liability, commercial arrangements, intellectual property, and other matters. While the outcome of these proceedings and claims cannot be predicted with certainty, there are no matters, as of November 6, 2015, that management believes would have a material adverse effect on our financial position, results of operations or cash flows.

**Item 1A. Risk Factors**

In addition to the information set forth in this report, you should consider the risks and uncertainties discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2014, which could materially affect our business, financial condition, or future results. There have been no substantive changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission on March 18, 2015.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds****Recent Sales of Unregistered Securities**

None.

**Issuer Purchases of Equity Securities**

Period	Issuer Purchases of Equity Securities			
	Total Number of Shares (or Units) Purchased (1)	Average Price Paid Per Share (or Unit)	Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Program	Maximum Number (or Approximate Dollar Value) of Shares (or Units) that may yet be Purchased under the Plans or Program
July 1, 2015 through July 31, 2015	23,180	\$ 11.24	N/A	N/A
August 1, 2015 through August 31, 2015		\$	N/A	N/A
September 1, 2015 through September 30, 2015		\$	N/A	N/A
Total	23,180	\$ 11.24	N/A	N/A

- (1) For the three months ended September 30, 2015, we repurchased 23,180 shares of our common stock to satisfy employees' obligations with respect to minimum statutory withholding taxes in connection with the vesting of restricted stock units.



**Table of Contents****Item 6. Exhibits**

<b>Exhibit</b>	<b>Exhibit Description</b>	<b>Incorporated by Reference</b>			<b>Filed</b>
		<b>Form</b>	<b>Date</b>	<b>Number</b>	<b>Herewith</b>
31.1	Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).				X
31.2	Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).				X
32.1	Certification by the Chief Executive Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).*				X
32.2	Certification by the Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).*				X
101.INS	XBRL Instance Document.				X
101.SCH	XBRL Taxonomy Extension Schema Document.				X
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.				X
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document				X
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.				X
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.				X

\* The certifications attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q, are not deemed filed with the SEC and are not to be incorporated by reference into any filing of LeMaitre Vascular, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on November 6, 2015.

LEMAITRE VASCULAR, INC

*/s/ George W. LeMaitre*

George W. LeMaitre

Chairman and Chief Executive Officer

*/s/ Joseph P. Pellegrino, Jr.*

Joseph P. Pellegrino, Jr.

Chief Financial Officer

**Table of Contents****EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Exhibit Description</b>	<b>Incorporated by Reference</b>			<b>Filed Herewith</b>
		<b>Form</b>	<b>Date</b>	<b>Number</b>	
31.1	Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).				X
31.2	Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).				X
32.1	Certification by the Chief Executive Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).*				X
32.2	Certification by the Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).*				X
101.INS	XBRL Instance Document.				X
101.SCH	XBRL Taxonomy Extension Schema Document.				X
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.				X
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document				X
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.				X
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.				X

\* The certifications attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q, are not deemed filed with the SEC and are not to be incorporated by reference into any filing of LeMaitre Vascular, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.